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suggest that assessment of regional brain volume changes using
voxel-based morphometry (VBM) would provide additional evi-
dence available from our existing MR data as to the pathophysi-
ological signiﬁcance of brain water and low grade cerebral
oedema in HE. In response to these comments, we have revisited
the structural scans acquired during our study and performed a
post hoc volumetric analysis of the brain in our patient group
by three different methods.
We compared the baseline 3D T1 weighted volumetric images
(TR/TE 9.6/4.6 ms, ﬂip angle 8, isotropic 1 mm resolution)
against the post amino acid challenge images using VBM
(SPM8) [3] for all subjects in a group analysis to identify any
areas of white and gray matter volume change. As an alternative
measure, we also compared individual subject data using the SIE-
NA approach (Structural Image Evaluation, using Normalisation,
of Atrophy, Version 2.2) [4], which provides a measurement of
the change in total brain volume between baseline and following
the challenge. Finally, we directly subtracted the co-registered
baseline and post challenge images for each subject. Images were
then visual inspected for evidence of volume change around the
brain–CSF boundary [5].
VBM analysis showed no statistically signiﬁcant areas of vol-
ume change in gray or white matter following the amino acid
challenge. Likewise, subtraction of co-registered images did not
reveal any visual evidence of shifts in the brain size. Formal
assessment of boundary shifts using SIENA showed a mean (±
SD) difference in total brain volume of –0.2 (± 0.69) percent
across all subjects, however the SIENA method is accurate to
around 0.2% brain volume change error [4], therefore these
results were deemed insigniﬁcant.
The results from this paired volumetric analysis showed no
signiﬁcant change in brain volume following the challenge. This
is consistent with the original ﬁndings of our paper in which we
concluded that ammonia can directly drive changes in brainwater
distribution, suggesting that glial swelling and the redistribution
of extra-intracellular water during hyperammonaemia are the
likely mechanism of cerebral oedema development in patients
with HE. Our ﬁndings do not support a vasogenic mechanism
for the transient changes in brain water diffusion seen following
transient, induced hyperammonaemia in this subject group.
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JOURNAL OF HEPATOLOGYTo the Editor:
Non-alcoholic fatty liver disease (NAFLD) is the most common
chronic liver disease in the world. It represents a wide spectrum
of conditions ranging from fatty liver, which in general follows a
benign, non-progressive clinical course, to nonalcoholic steato-
hepatitis (NASH), a more serious form of NAFLD that may progress
to cirrhosis and end-stage liver disease. Accurate evaluation of
liver ﬁbrosis in patients with NAFLD is important to identify
patients who may develop complications. Over time, several bio-
logical markers have been studied for evaluating the extent of ste-
atosis, the presence of necroinﬂammation, and the development
of ﬁbrosis to avoid performing liver biopsy, an invasive procedure
that still represents the gold standard of diagnosis. The most
important parameter to be identiﬁed through non-invasive
methods is inﬂammation, as it plays a central role in NAFLD pro-
gression. Several biomarkers of inﬂammation were extensively
studied in relation to fatty liver disease. The C reactive proteinJournal of Hepatology 2(CRP) is an acute-phase reactant produced by the liver and has
an increased serum concentration in a variety of inﬂammatory
conditions. The assessment of circulating levels of high sensitive
CRP (hsCRP) proved to be useful in differentiating between simple
steatosis and NASH. Moreover, it seems that high concentrations
of hsCRP are associated with extensive liver ﬁbrosis in NASH [1].
In a recent issue of the Journal of Hepatology, Zimmermann
et al. reported the association of hsCRP with various features of
NAFLD in a large obese population. The authors concluded that,
based on their results, hsCRP may be a marker of steatosis, but
not of severity of NAFLD in these patients [2]. The ﬁndings of this
report are interesting and contribute to our understanding of this
issue. However, we have some concerns about the data presented
by the authors.
Firstly, circulating hsCRP levels have been reported to be ele-
vated in subjects with diabetes mellitus (DM) and also prediabe-
tes [3,4]. Although it was stated in the article that some of the012 vol. 56 j 503–510 507
patients were diabetic at baseline, there is no information regard-
ing the glucose tolerance status of the other subjects. It is well
known that NAFLD is strongly associated with obesity, hyperten-
sion, dyslipidemia and also glucose tolerance abnormalities [5].
In addition, all these metabolic problems are risk factors for
DM and also prediabetes. In light of these data, we think that
some of the study participants may still have overt glucose dys-
regulation or DM without implementation of the glucose toler-
ance test. Secondly, there is no data about the blood pressure
and lipid proﬁles of the study participants. A large body of evi-
dence shows that circulating levels of hsCRP differ according to
the degree of lipid disorders [6]. This point is also true for hyper-
tension or elevated blood pressure [7]. On the other hand, meta-
bolic syndrome is also strongly associated with circulating hsCRP
levels [8]. Lastly, no information about the medications could be
seen in the text. We know that hsCRP levels are easily affected
from the medications started for the metabolic problems men-
tioned above [9,10]. Collectively, all these points raise several
questions warranting discussion.
We conclude that, before making certain interpretations, pres-
ence of major confounders raises some questions about the data
presented. In such a case, statistical correlations may also be mis-
leading. It would be appreciated if the authors could present
some more data adjusted for topics mentioned above. This could
provide the readers of the Journal clearer information regarding
the relationship of hsCRP with this clinically relevant condition.
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Reply to: ‘‘C-reactive protein levels in non-alcoholic fatty
liver disease’’
To the Editor:
We thank Dr. Dogru et al. for their comments on our paper on
C-reactive protein (CRP) levels in relation to various features of
non-alcoholic fatty liver disease (NAFLD) among obese patients
[1]. In our study of 627 obese adults with liver histology and
measures of body mass index (BMI, kg/m2), and high sensitivity
(hs)-CRP, we conﬁrmed a strong association between BMI and
hs-CRP, with a 20% increase in hs-CRP level per 10% increase in
BMI. Also, we observed a positive association between hs-CRP
and liver steatosis, but no BMI independent association between
hs-CRP and non-alcoholic steato-hepatitis (NASH), hence ques-
tioning whether CRP can be used as a marker of severity of NAFLD
[1].
We fully acknowledge that circulating hs-CRP levels may not
only associate with obesity, but also with pre-diabetes and dia-
betes [2,3], which in turn may associate with NAFLD [4]. How-
ever, obesity (which was adjusted for by use of BMI) is also
strongly associated with both diabetes and NAFLD [5]. Therefore,
further adjustment for diabetes or glucose tolerance abnormali-
ties would not be expected to change our results notably. The
same argument holds for the effect of further adjustment for
hypertension and lipid proﬁles. Still, to meet the concern of
Dr. Dogru et al., we have reassessed the mentioned metabolic
factors in two of the study cohorts. We can now report that in
the OBBO cohort, hs-CRP was associated with triglycerides
(p = 0.02), but not with glucose tolerance status (test across cat-
egories of normal glucose tolerance, impaired fasting glucose
[IFG], impaired glucose tolerance [IGT], combined IFG-IGT, and
diabetes), systolic or diastolic blood pressure, total cholesterol,
HDL-cholesterol, or LDL-cholesterol. In the Nice Obese Subjects
cohort, we observed a negative association between CRP and
high blood pressure (p = 0.002), but no association between
CRP and, respectively, diabetes, glucose intolerance, triglyceride
levels, HDL-cholesterol, or the metabolic syndrome. Hence,
adjustment for triglycerides and blood pressure could be consid-
ered, but would, due to the association with BMI, not be
expected to change conclusions.
An additional concern raised by Dr. Dogru et al. was the effect
of medications on the observed associations. A reduction in hs-
CRP caused by medications given primarily to patients with
severe metabolic disturbances and related severe NAFLD, could
hypothetically explain our ﬁnding of no association between
hs-CRP levels and severity of NAFLD. Our reassessment of the
OBBO cohort revealed that hs-CRP was not associated with
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